Treatment with decitabine was shown to demethylate promoters and restore/induce the expression of the silenced RORA and BCL2 in autistic and patients with fragile X syndrome and hence, the use of DNA demethylating agents in drug therapy for autism and fragile X syndrome has been suggested [61,62]. This evidence concerns the gene BCL2 and fragile X syndrome.